These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25321188)
1. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence. Saleh MI Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188 [TBL] [Abstract][Full Text] [Related]
2. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329 [TBL] [Abstract][Full Text] [Related]
3. Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine. Saleh MI Eur Rev Med Pharmacol Sci; 2014; 18(24):3935-42. PubMed ID: 25555887 [TBL] [Abstract][Full Text] [Related]
4. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018 [TBL] [Abstract][Full Text] [Related]
5. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113 [No Abstract] [Full Text] [Related]
6. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382 [TBL] [Abstract][Full Text] [Related]
7. Group medication management for buprenorphine/naloxone in opioid-dependent veterans. Berger R; Pulido C; Lacro J; Groban S; Robinson S J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875 [TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241 [TBL] [Abstract][Full Text] [Related]
10. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
12. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Curcio F; Franco T; Topa M; Baldassarre C; Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796 [TBL] [Abstract][Full Text] [Related]
13. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242 [TBL] [Abstract][Full Text] [Related]
16. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice. Van Doren BA; Foulks-Rodriguez KA; Yarborough W J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769 [TBL] [Abstract][Full Text] [Related]
17. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887 [TBL] [Abstract][Full Text] [Related]
18. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment. Renzelli CM; Capretto NA J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874 [TBL] [Abstract][Full Text] [Related]
19. Early experience with Suboxone maintenance therapy in Hungary. Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662 [TBL] [Abstract][Full Text] [Related]
20. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Correia CJ; Walsh SL; Bigelow GE; Strain EC Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]